ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
NAV
₹47.27
as of 21 Aug 2026
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is an open-ended Sectoral/ Thematic scheme from ICICI Prudential Mutual Fund managing ₹6,803 crore (as of 31 Jul 2026). Its Direct-plan NAV is ₹47.27 as of 21 Aug 2026. The expense ratio is 0.86% a year. Managed by Dharmesh Kakkad. This page is factual data only — it carries no rating and no recommendation.
Key facts
- Expense ratio
- 0.86% / yr
- as of 30 Jun 2026
- Fund size
- ₹6,803 crore
- as of 31 Jul 2026
- Exit load
- 1%
- SIP available
- Yes
- Launched
- 12 Jul 2018
- ISIN
- INF109KC1GH2
₹100 invested, fund vs category
The category line is the average of the funds in this category, built from NYVO’s own NAV data.
Rebased to 100data to 20 Aug 2026Benchmark: Nifty 500 Healthcare TRI
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
₹219
+119% on ₹100 over 5.0 yrs
Sectoral/ Thematic average
₹210
+110% on ₹100 over 5.0 yrs
Returns vs category
| Window | Fund | Category avg | Gap |
|---|---|---|---|
| 3 months | 3.97% | 6.78% | -2.81 |
| 6 months | 14.14% | 3.68% | +10.46 |
| 1 year | 9.02% | 6.07% | +2.95 |
| 3 years (CAGR) | 23.00% | 16.01% | +6.99 |
| 5 years (CAGR) | 16.93% | 15.20% | +1.73 |
Category average across 119 funds, as of 21 Aug 2026. Short windows are noise; the 3 and 5-year rows are the record. Past returns do not predict future returns.
A single return number depends on its start date. These are ALL the overlapping holding periods, so the worst case is visible — read that number first.
1-year holding periods
- Worst
- -11.5%
- Median
- 14.5%
- Best
- 64.8%
49 windows over the last 60 months, stepped monthly; 82% ended positive. Worst window began 1 Sept 2021. Windows overlap — this is the range of past start dates, not a probability of anything.
3-year holding periods (per year)
- Worst
- 20.4%
- Median
- 26.6%
- Best
- 30.8%
25 windows over the last 60 months, stepped monthly; 100% ended positive. Worst window began 2 Aug 2021. Windows overlap — this is the range of past start dates, not a probability of anything.
Risk, measured
- Sharpe ratio (3Y)
- 1.04
- Sharpe ratio (5Y)
- 0.72
- Sortino ratio (3Y)
- 1.78 vs category 1.55
- Standard deviation (3Y)
- 16.11%
- Beta (3Y)
- 0.96
- Alpha (3Y)
- 2.03%
- Deepest fall (5Y)
- -15.97%
Distance below its own peak
Every dip below 0 is the fund trading under a previous high — how deep and for how long is what a drawdown feels like.
Deepest fall
-15.6%
Right now
-2.0% below peak
Ahead of its benchmark in 56% of months (window: 3y, monthly) — benchmark: Nifty 500 Healthcare TRI, name shown only.
Where the money actually is
Equity
97.2%
Cash
2.8%
Whole-portfolio split, as of 31 Jul 2026.
What it owns
38 positions · top 10 = 60.3%
Market-cap mix
Large 25.3%Mid 32.5%Small 38.7%Other 3.6%
as of 31 Jul 2026
Holdings by sector
Healthcare(10 in top 10)96.0%
- Sun Pharmaceuticals Industries Ltd12.69%
- Dr Reddy's Laboratories Ltd8.45%
- Cipla Ltd6.56%
- Divi's Laboratories Ltd6.03%
- Mankind Pharma Ltd5.47%
- Alkem Laboratories Ltd5.11%
- Biocon Ltd4.97%
- Cohance Lifesciences Ltd3.92%
- Medplus Health Services Ltd3.80%
- Syngene International Ltd3.26%
- Basic Materials1.2%
Sectors marked ▶ expand to show this fund’s top-10 holdings in that sector. Holdings as of 31 Jul 2026. Portfolio turnover 82.5% vs category 37.3% a year.
The businesses it owns
- P/E (trailing)
- 38.5 vs category 25.8
- P/B
- 4.3 vs category 3.8
- Dividend yield
- 0.7% vs category 1.1%
- Net margin
- 13.9% vs category 15.4%
- Earnings growth
- 13.7%
- Avg market cap
- ₹50,085 crore
Money in, money out
- Net flow, 12 months
- +₹245 cr
- Net flow, 3 months
- −₹451 cr
as of 31 Jul 2026. Flows follow performance more than they predict it.
Quick answers
- What is the NAV of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund?
- ₹47.27 per unit as of 21 Aug 2026 (Direct plan, growth). NAV is declared daily on working days.
- What is the expense ratio of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund?
- 0.86% a year for the Direct plan, as of 30 Jun 2026.
- How large is ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund?
- ₹6,803 crore under management as of 31 Jul 2026, in the Sectoral/ Thematic category.
- How risky is ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund?
- Its SEBI Riskometer reading is "Very High Risk". One sector, one story. The most-launched shelf on the map, by far.
- What are the 5-year returns of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund?
- 16.93% a year over the last 5 years (Direct plan, CAGR), against a Sectoral/ Thematic average of 15.20%. Past returns do not predict future returns.
- What is the worst 3-year return of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund?
- 20.4% a year — the weakest of 25 overlapping 3-year holding periods, beginning 2 Aug 2021. The median was 26.6% and 100% of those windows ended positive. Windows overlap, so this is the range of past start dates, not a probability.
- Who manages ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund?
- Dharmesh Kakkad, managing this fund for 6.2 years.
Where this fund sits
Its shelf, all funds
St · Sectoral / thematic →
One sector, one story. The most-launched shelf on the map, by far.
The money map
How big this shelf is in India →
The whole industry sized by real money, from AMFI’s monthly data.
Side by side
Compare this fund →
Put it next to any other fund — growth, returns, risk and cost in one table.
One bet or two?
Check its overlap →
See whether it owns the same stocks as your other funds.
Other Sectoral/ Thematic funds
- ICICI Prudential India Opportunities Fund₹38,299 crore
- ICICI Prudential Business Cycle Fund₹16,123 crore
- ICICI Prudential Technology Fund₹13,540 crore
- ICICI Prudential Banking & Financial Services Fund₹11,229 crore
- Nippon India Banking & Financial Services Fund₹7,774 crore
- ICICI Prudential Manufacturing Fund₹7,148 crore
- SBI PSU FUND₹6,678 crore
- SBI MNC FUND₹6,481 crore
Data: NYVO research systems; each block above states its own as-of date, and blocks with no data for this fund are omitted rather than estimated. NAV updates daily on working days. The benchmark (Nifty 500 Healthcare TRI) is named for reference only; its values are licensed and never shown. This page is factual information about one scheme. It is not investment advice, not a recommendation, and it carries no rating of any kind. Past performance does not predict future returns. Mutual fund investments are subject to market risks; read all scheme related documents carefully.